{
  "abstract": "India’s pharmaceutical and clinical research sectors stand at a critical inflection point. As the world’s third-largest medicine producer by volume and an emerging hub for biologics, diagnostics and digital therapeutics, India requires a regulatory framework that is agile, transparent and grounded in scientific expertise. While recent steps by the Central Drugs Standard Control Organisation (CDSCO), including e-governance platforms and updated trial rules, are commendable, persistent challenges constrain its effectiveness.",
  "authors": [
    {
      "affiliations": [
        "Diabetes and Allergy-Asthma Therapeutics Specialty Clinic, Kolkata, India"
      ],
      "name": "Shambo Samrat Samajdar"
    },
    {
      "affiliations": [
        "Department of Pharmacology, Himalaya Medical College & Hospital, Chiksi, Paliganj, Patna, Bihar, India"
      ],
      "name": "Noor Husain"
    },
    {
      "affiliations": [
        "Diabetes Hormone Clinic, Ahmedabad, India"
      ],
      "name": "Banshi Saboo"
    },
    {
      "affiliations": [
        "Joshi Clinic & Lilavati Hospital and Research Centre, Mumbai, India"
      ],
      "name": "Shashank R Joshi"
    }
  ],
  "title": "Towards a unified, science-led regulatory ecosystem in India: the case for BhaRATH",
  "uid": "f7fbc0b4-d185-508e-a74f-15b1a3eee63f"
}